Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder
- 1 November 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Clinical Psychopharmacology
- Vol. 22 (6), 313-322
- https://doi.org/10.1097/yic.0b013e32825ea312
Abstract
Convincing evidence from placebo-referenced randomized controlled trials supports efficacy for clomipramine and selective serotonin reuptake inhibitors for acute treatment of obsessive-compulsive disorder. It remains less conclusively understood whether these agents maintain efficacy over the longer term. This paper systematically reviews long-term medication studies in obsessive-compulsive disorder. Studies of clomipramine, fluoxetine and sertraline investigated 'responders' from acute treatment trials and extended treatment up to 12 months versus placebo. Responses to medication were sustained. A 24-week placebo-controlled trial of escitalopram (10 mg or 20 mg/day) and paroxetine (40 mg/day) demonstrated ongoing efficacy for all three treatments. Studies that randomized treated cases to placebo demonstrated reemergence of symptoms in the placebo-treated cohort. Six relapse prevention trials were found by systematic search. Some, but not all, revealed significant advantages for remaining on medication. Paroxetine (20-60 mg/day) and escitalopram (10 or 20 mg/day) were each found to outperform placebo in preventing relapse during 24 weeks of double-blind, randomized follow-up. Meta-analysis, using Review Manager software (4.2.8), detected overall superiority of selective serotonin reuptake inhibitors to placebo in preventing relapse among adult treatment-responders. Worsening by five Yale-Brown Obsessive Compulsive Scale points emerged from the review as a suggested threshold for relapse. Viewed collectively, these results suggest that selective serotonin reuptake inhibitors are effective long-term treatments and relapse prevention represents the treatment target for obsessive-compulsive disorder.Keywords
This publication has 50 references indexed in Scilit:
- Escitalopram prevents relapse of obsessive-compulsive disorderEuropean Neuropsychopharmacology, 2007
- What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?British Journal of Psychology, 2006
- Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2005
- Increased Maintenance of Obsessive-Compulsive Disorder Remission after Integrated Serotonergic Treatment and Cognitive Psychotherapy Compared with Medication AlonePsychotherapy and Psychosomatics, 2005
- Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive DisorderAmerican Journal of Psychiatry, 2005
- A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorderClinical Psychology Review, 2004
- A Randomized Controlled Trial of Cognitive Therapy versus Intensive Behavior Therapy in Obsessive Compulsive DisorderPsychotherapy and Psychosomatics, 2001
- Evidence-based pharmacotherapy of obsessive–compulsive disorderInternational Journal of Neuropsychopharmacology, 1999
- A Controlled Study of Fluvoxamine and Exposure in Obsessive-Compulsive DisorderInternational Clinical Psychopharmacology, 1990
- Clomipramine Treatment of Childhood Obsessive-Compulsive DisorderArchives of General Psychiatry, 1985